QuicDNA Max

• Research type

  Research Study

• Full title

  QuicDNA Max Research Programme (multi-site)

• IRAS ID

  363293

• Contact name

  Magdalena Meissner

• Contact email

  magdalena.meissner@wales.nhs.uk

• Sponsor organisation

  Cardiff & Vale University Health Board

• ISRCTN Number

  ISRCTN00000000

• Clinicaltrials.gov Identifier

  N/A, N/A

• Duration of Study in the UK

  3 years, 0 months, 0 days

• Research summary

  QuicDNA Max is a research programme exploring how a blood test, called a liquid biopsy, can help doctors better understand and treat cancer. This test looks for cancer-related DNA in the blood, which can help guide treatment decisions and track how the disease changes over time.

  The programme will start by focusing on the following cancers, but more will be added if funding allows:
  Lung cancer that has stopped responding to targeted therapy
  Cancer of unknown primary (when doctors do not know in which part of the body the cancer started)
  Bowel (colorectal) cancer
  Prostate cancer

  The QuicDNA Max research programme aims to:

  - Improve diagnosis and treatment access, especially for cancers that are hard to test using traditional methods or change over time.
  - Provide real-world evidence to support wider NHS use of liquid biopsy testing.
  - Help the NHS save time and resources.
  - Make genetic testing routine in NHS Wales cancer care.
  - Build a skilled diagnostic workforce for future needs.
  - Assess cost-effectiveness to inform NHS funding decisions.

  This programme will provide an opportunity for improving NHS services and expanding research through:
  - collaboration with NHS decision-makers to plan future services
  - partnership with universities, NHS, and industry
  - support to the NHS staff with training and innovation
  - encouraging related research aligned with the programme goals
  - positioning Wales as a leader in advanced genetic cancer testing

  QuicDNA Max supports the Welsh Government’s vision to enhance cancer care and integrate cutting-edge technologies into everyday NHS services. It is delivered in partnership with NHS Wales, the Welsh Government, the Office for Life Sciences, and others to keep Wales at the forefront of cancer innovation.

• REC name

  Wales REC 2

• REC reference

  25/WA/0307

• Date of REC Opinion

  29 Dec 2025

• REC opinion

  Further Information Favourable Opinion